TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28482070

Group type: EXPERIMENTAL
Intervention: Elevated fasting α-hydroxybutyrate levels
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Plasma α-hydroxybutyrate and BCAAs during OGTT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Baseline α-hydroxybutyrate concentrations
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Progressive α-hydroxybutyrate decrease
Number of subjects: 78
Study: 28482144

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg subcutaneously every 6 weeks during period 1 (P1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Canakinumab treatment during period 1 (P1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Canakinumab treatment during period 2 (P2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Canakinumab treatment
Number of subjects: 9
Study: 28482146

Group type: EXPERIMENTAL
Intervention: Skeletal muscle fat (SMF) measurement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intermuscular adipose tissue (IMAT) measurement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT) measurement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Performance-based tests (quadriceps muscle strength, gait speed, repeated chair-stands, stair ascent, single-leg stance)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Activity monitor for physical activity assessment
Number of subjects: 60
Study: 28482689

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28482711

Group type: EXPERIMENTAL
Intervention: Presence of M protein
Number of subjects: 667

Group type: COMPARATOR
Intervention: No M protein
Number of subjects: 667
Study: 28482908

Group type: EXPERIMENTAL
Intervention: Adenovirus-specific T cell (ADV-VST) infusion from HSCT donor or third party haploidentical donor
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adenovirus-specific T cell (ADV-VST) infusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of ADV-VST
Number of subjects: 14
Study: 28482919

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 1
Study: 28483654

Group type: EXPERIMENTAL
Intervention: Robot-based assessments (wrist targeting, finger targeting, finger movement speed, reaction time, robotic version of the Box and Block test)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Robot-based assessments (wrist targeting, finger targeting)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Robotic version of the Box and Block test (BBT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Robot-based assessments
Number of subjects: 40
Study: 28483716

Group type: EXPERIMENTAL
Intervention: Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease (MRD) test and graft-versus-host disease (GVHD)-guided multiple DLIs.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Receiving 1 course of DLI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Positive MRD test
Number of subjects: 100
Study: 28483741

Group type: EXPERIMENTAL
Intervention: Mass emails to the student body
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: College websites and learning management systems
Number of subjects: 1452
Study: 28483761

Group type: EXPERIMENTAL
Intervention: Isatuximab-lenalidomide-dexamethasone
Number of subjects: 57
Study: 28483828

Group type: EXPERIMENTAL
Intervention: Sodium added to food outside the home
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Sodium inherent to food
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Salt added in home food preparation
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Salt added to food at the table
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Home tap water consumed as a beverage and dietary supplement and nonprescription antacids
Number of subjects: 450
Study: 28483965

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) at a dose of 25 mg/kg of body weight/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 52
Study: 28484421

Group type: EXPERIMENTAL
Intervention: PCTus-based antibiotic therapy guidance in addition to stroke unit care
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard stroke unit care alone
Number of subjects: 227
Study: 28484424

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 22
Study: 28484650

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical treatment (keyhole approach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gold standard surgical treatment (not specified)
Number of subjects: 0
Study: 28484830

Group type: EXPERIMENTAL
Intervention: CoreValve prosthesis implantation
Number of subjects: 996
Study: 28484920

Group type: EXPERIMENTAL
Intervention: Offsite expert guidance via social network video call
Number of subjects: 60

Group type: COMPARATOR
Intervention: Onsite cardiologist's echocardiography using modified Simpson's method
Number of subjects: 60
Study: 28484958

Group type: EXPERIMENTAL
Intervention: Diuretic resistance defined by fractional sodium excretion (FeNa) <0.2%
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Diuretic resistance defined by urinary sodium <50 meq/L
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Diuretic resistance defined by urinary Na/K ratio <1.0
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Readmission or death within 30 days
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Comparison of definitions of diuretic resistance
Number of subjects: 1033
Study: 28484982

Group type: EXPERIMENTAL
Intervention: Self-Affirmation
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study: 28485687

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 36
Study: 28485816

Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 1938

Group type: COMPARATOR
Intervention: Classic systemic therapies
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1938
Study: 28486553

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control
Number of subjects: 438
Study: 28486646

Group type: EXPERIMENTAL
Intervention: Patients with MINS
Number of subjects: 475
Study: 28486991

Group type: EXPERIMENTAL
Intervention: eQ Connect™ intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28487034

Group type: EXPERIMENTAL
Intervention: Multiple biomarker score including NT-proBNP, kidney injury molecule-1, osteopontin, and tissue inhibitor of metalloproteinase-1
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Multiple biomarkers
Number of subjects: 649
Study: 28487264

Group type: EXPERIMENTAL
Intervention: Protein-fortified diet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 38
Study: 28487491

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally daily on days 1-21 of a 28-day cycle
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 18
Study: 28487648

Group type: EXPERIMENTAL
Intervention: Group-based exercise training
Number of subjects: 0
Study: 28487769

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Number of subjects: 0
Study: 28488169

Group type: EXPERIMENTAL
Intervention: Cerebral oxygen desaturation in hypertensive patients during surgery
Number of subjects: 0
Study: 28489488

Group type: EXPERIMENTAL
Intervention: Various known and newly identified targets to prevent or mitigate RIF in pre-clinical models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimally designed preclinical models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrating appropriate endpoints in clinical trials
Number of subjects: 0
Study: 28489510

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for up to 24 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 24
Study: 28489732

Group type: EXPERIMENTAL
Intervention: NVP prophylactic dosing (WHO weight-band recommendations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NVP therapeutic dosing (6 mg/kg twice daily)
Number of subjects: 60
Study: 28490433

Group type: EXPERIMENTAL
Intervention: Peripheral blood interleukin-6 (IL-6) levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Increased peripheral blood platelet-derived growth factor BB glycoprotein
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Blocking IL-1R or IL-6R
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Increased IL-6 levels
Number of subjects: 87
Study: 28490511

Group type: EXPERIMENTAL
Intervention: Breakfast skipping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dinner skipping
Number of subjects: 0
Study: 28490569

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 18
Study: 28492122

Group type: EXPERIMENTAL
Intervention: Unplanned admissions
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Overall admissions
Number of subjects: 255

Group type: COMPARATOR
Intervention: Planned admissions
Number of subjects: 255
Study: 28493515

Group type: EXPERIMENTAL
Intervention: 2-day measurement procedure combining a 3-hour 75-g oral glucose tolerance test and a 2-stage hyperglycaemic clamp procedure, augmented with arginine
Number of subjects: 0
Study: 28493866

Group type: EXPERIMENTAL
Intervention: CART predictive model for BA versus Non-BA
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Stepwise logistic regression model
Number of subjects: 401
Study: 28494071

Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometry (DCT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Discordance between DCT and GAT
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Corrected GAT values
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dresdner correction formula
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Glaucoma Severity Score
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Uncorrected discordance IOPDCT - IOPGAT
Number of subjects: 112
Study: 28494135

Group type: EXPERIMENTAL
Intervention: Midlife Body Mass Index (BMI)
Number of subjects: 2733
Study: 28494506

Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (HMA) including decitabine (DAC) and azacitidine (AZA) after induction/consolidation with fludarabine, cytarabine, and G-CSF (FLAG) with low dose gemtuzumab or idarubicin.
Number of subjects: 23
Study: 28494686

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 0
Study: 28494788

Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 436
Study: 28494798

Group type: EXPERIMENTAL
Intervention: chronic low-dose step up protocol with recombinant human FSH (rhFSH)
Number of subjects: 107

Group type: COMPARATOR
Intervention: not available
Number of subjects: 107
Study: 28494812

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study: 28495029

Group type: EXPERIMENTAL
Intervention: Delafloxacin 450 mg every 12 hours from days 3 to 8
Number of subjects: 22

Group type: COMPARATOR
Intervention: Midazolam 5 mg oral dose on days 1 and 8
Number of subjects: 22
Study: 28495354

Group type: EXPERIMENTAL
Intervention: Tafenoquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28495639

Group type: EXPERIMENTAL
Intervention: CPI-613 in combination with modified FOLFIRINOX (oxaliplatin at 65 mg/m², leucovorin, irinotecan, and fluorouracil)
Number of subjects: 20
Study: 28495794

Group type: EXPERIMENTAL
Intervention: Complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after enrollment
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Complete or partial response
Number of subjects: 328

Group type: COMPARATOR
Intervention: Stable or progressive disease
Number of subjects: 328
Study: 28495804

Group type: EXPERIMENTAL
Intervention: Labral repair (n=40)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Biceps tenodesis (n=39)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sham surgery (n=39)
Number of subjects: 118
Study: 28495814

Group type: EXPERIMENTAL
Intervention: Automated control of mechanical ventilation during general anaesthesia
Number of subjects: 0
Study: 28495896

Group type: EXPERIMENTAL
Intervention: SVG PCI
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: HPR
Number of subjects: 405
Study: 28495897

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3280

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 3280

Group type: COMPARATOR
Intervention: Overall analysis from SYNTAX, PRECOMBAT, and BEST trials
Number of subjects: 3280
Study: 28497070

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400/propylene glycol/hydroxypropyl-guar quid for 6 weeks (SG1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate provided in the COMOD® device quid for 6 weeks (SG2)
Number of subjects: 180

Group type: COMPARATOR
Intervention: FCTD quid for 3 weeks (CG)
Number of subjects: 180
Study: 28497258

Group type: EXPERIMENTAL
Intervention: Veliparib administered orally at doses ranging from 10 to 80 mg twice daily on days 1-7
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Temozolomide administered orally at 150-200 mg/m2
Number of subjects: 42
Study: 28497757

Group type: EXPERIMENTAL
Intervention: Veliparib (400 mg twice daily) combined with capecitabine (825 mg/m2) and radiotherapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Veliparib plus capecitabine and radiotherapy
Number of subjects: 32
Study: 28498187

Group type: EXPERIMENTAL
Intervention: Structured Mentor Mother (MM) support
Number of subjects: 497

Group type: COMPARATOR
Intervention: Routine peer support (Control)
Number of subjects: 497
Study: 28498188

Group type: EXPERIMENTAL
Intervention: Structured Mentor Mother (MM) support
Number of subjects: 497

Group type: COMPARATOR
Intervention: Routine but ad hoc peer support (PS)
Number of subjects: 497
Study: 28498190

Group type: EXPERIMENTAL
Intervention: Option B+ ART initiation with same-day initiation regardless of CD4 count
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Younger women, newly diagnosed with HIV, and/or first presenting to antenatal care in their third trimester
Number of subjects: 1150
Study: 28498193

Group type: EXPERIMENTAL
Intervention: Expert Mothers (EMs) involvement in PMTCT programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Challenges faced by EMs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Need for coordinated action
Number of subjects: 0
Study: 28498618

Group type: EXPERIMENTAL
Intervention: CDCA1 peptide vaccination (1.0 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CDCA1 peptide vaccination (3.0 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CDCA1 peptide vaccination
Number of subjects: 12
Study: 28498856

Group type: EXPERIMENTAL
Intervention: Crystalloids (84.3% of patients receiving resuscitation fluid)
Number of subjects: 6707

Group type: EXPERIMENTAL
Intervention: Colloids (27.1% of patients receiving resuscitation fluid)
Number of subjects: 6707

Group type: COMPARATOR
Intervention: Traumatic brain injury patients
Number of subjects: 6707

Group type: EXPERIMENTAL
Intervention: Patients in ICU for one or more days
Number of subjects: 6707
Study: 28498880

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (30 mg/m2 docetaxel, 40 mg/m2 cisplatin, 2000 mg/m2 fluorouracil per week)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 54
Study: 28499385

Group type: EXPERIMENTAL
Intervention: Prevalent cardio-renal target organ damage (TOD) including left ventricular hypertrophy (LVH), left atrium (LA) dilatation, and high urine albumin/creatinine ratio (UACR)
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Body fat and inflammatory markers introduced into the model
Number of subjects: 2887
Study: 28499389

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tumor resection and combined radio-chemotherapy
Number of subjects: 32
Study: 28499958

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 17
Study: 28500178

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation for elimination of arrhythmogenic electrophysiological substrate (AES)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ajmaline for mapping of AES
Number of subjects: 135

Group type: COMPARATOR
Intervention: Implantable cardiac defibrillator shocks
Number of subjects: 135
Study: 28501139

Group type: EXPERIMENTAL
Intervention: alectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: crizotinib
Number of subjects: 0
Study: 28501738

Group type: EXPERIMENTAL
Intervention: Interpersonal Support Evaluation List (ISEL)
Number of subjects: 0
Study: 28501811

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with advanced virtual stenting technique and porous media method for haemodynamic simulations.
Number of subjects: 200
Study: 28501909

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist therapy (VKA)
Number of subjects: 5707
Study: 28502418

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (fixed-dose strategy)
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (SMART strategy)
Number of subjects: 1483
Study: 28502872

Group type: EXPERIMENTAL
Intervention: S-ICD implantation
Number of subjects: 1637
Study: 28502892

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adequate initial antibiotic therapy
Number of subjects: 37
Study: 28503188

Group type: EXPERIMENTAL
Intervention: High linoleic acid (LA) intake from soy oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low linoleic acid (LA) intake from soy oil
Number of subjects: 0
Study: 28503190

Group type: EXPERIMENTAL
Intervention: 10 g of essential amino acids (EAA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 10 g of essential amino acids (EAA) with chloroquine (CQ)
Number of subjects: 13
Study: 28503712

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg subcutaneous once weekly (qw)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg subcutaneous every 2 weeks (q2w)
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1379
Study: 28504047

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IVUS
Number of subjects: 47
Study: 28504860

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) expanded in vitro, dose 1-2 × 10^6 cells/kg
Number of subjects: 74
Study: 28504996

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 7 mL/kg administered for 30 minutes after opening the thoracic cavity.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stroke Volume Variation (SVV) before fluid challenge.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV) before fluid challenge.
Number of subjects: 80
Study: 28505243

Group type: EXPERIMENTAL
Intervention: High dual-task gait cost while counting backward
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: High dual-task gait cost while naming animals
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Slow single-task gait velocity (<0.8 m/second)
Number of subjects: 112
Study: 28505327

Group type: EXPERIMENTAL
Intervention: SAHA (1 µM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SAHA (5-day intraperitoneal administration)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SAHA (1 µM/24 h)
Number of subjects: 8
Study: 28505364

Group type: EXPERIMENTAL
Intervention: IGF-I measurement using six different immunoassays
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Normative data for IGF-I from the same six assay kits
Number of subjects: 102
Study: 28505487

Group type: EXPERIMENTAL
Intervention: Heroin refusal self-efficacy
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Depressed mood
Number of subjects: 397

Group type: COMPARATOR
Intervention: No MAT
Number of subjects: 397
Study: 28506243

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Preference for comfort measures over life support
Number of subjects: 1671
Study: 28506306

Group type: EXPERIMENTAL
Intervention: Tailored patient education course
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Surgical treatment during the study period
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Baseline mental health
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Increasing self-esteem and self-efficacy
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Self-esteem and self-efficacy
Number of subjects: 142
Study: 28506390

Group type: EXPERIMENTAL
Intervention: OM3-CA 4 g once daily for 13 days with rosuvastatin 40 mg (single dose) co-administered with the 11th dose.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Simvastatin 40 mg plus acetylsalicylic acid 81 mg daily for 14 days with or without OM3-CA.
Number of subjects: 111
Study: 28506446

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 680

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 680
Study: 28506516

Group type: EXPERIMENTAL
Intervention: 5 doses of DTaP vaccine
Number of subjects: 4181

Group type: EXPERIMENTAL
Intervention: Any DTaP vaccine
Number of subjects: 4181
Study: 28506784

Group type: EXPERIMENTAL
Intervention: Healthcare personnel (HCP) caring for MDRO-colonized patients
Number of subjects: 800

Group type: COMPARATOR
Intervention: Staff without patient contact
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 800
Study: 28507113

Group type: EXPERIMENTAL
Intervention: Binuclear Cyclopalladated Compound Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28507117

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study: 28507981

Group type: EXPERIMENTAL
Intervention: Movement and preliteracy skill program (1 hour/week for 10 weeks)
Number of subjects: 19
Study: 28508253

Group type: EXPERIMENTAL
Intervention: DEBDOX treatment
Number of subjects: 20